Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 ONTARGET: questions asked, questions answered.

× No keyword cloud information.

14 in total

Review 1. Adverse effects of combination angiotensin II receptor blockers plus angiotensin-converting enzyme inhibitors for left ventricular dysfunction: a quantitative review of data from randomized clinical trials.

Authors: Christopher O Phillips; Amir Kashani; Dennis K Ko; Gary Francis; Harlan M Krumholz
Journal: Arch Intern Med Date: 2007-10-08

Review 2. Inhibiting the renin-angiotensin system to prevent cardiovascular diseases: do we need a more comprehensive strategy?

Authors: Michael A Weber; Thomas D Giles
Journal: Rev Cardiovasc Med Date: 2006 Impact factor: 2.930

3. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.

Authors: Jackson T Wright; George Bakris; Tom Greene; Larry Y Agodoa; Lawrence J Appel; Jeanne Charleston; DeAnna Cheek; Janice G Douglas-Baltimore; Jennifer Gassman; Richard Glassock; Lee Hebert; Kenneth Jamerson; Julia Lewis; Robert A Phillips; Robert D Toto; John P Middleton; Stephen G Rostand
Journal: JAMA Date: 2002-11-20 Impact factor: 56.272

Review 4. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension.

Authors: David B Matchar; Douglas C McCrory; Lori A Orlando; Manesh R Patel; Uptal D Patel; Meenal B Patwardhan; Benjamin Powers; Gregory P Samsa; Rebecca N Gray
Journal: Ann Intern Med Date: 2007-11-05 Impact factor: 25.391

5. Mortality rates in elderly patients who take different angiotensin-converting enzyme inhibitors after acute myocardial infarction: a class effect?

Authors: Louise Pilote; Michal Abrahamowicz; Eric Rodrigues; Mark J Eisenberg; Elham Rahme
Journal: Ann Intern Med Date: 2004-07-20 Impact factor: 25.391

6. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Authors: John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Journal: Lancet Date: 2003-09-06 Impact factor: 79.321

Review 7. New opportunities in cardiovascular patient management: a survey of clinical data on the combination of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.

Authors: Michael A Weber
Journal: Am J Cardiol Date: 2007-05-25 Impact factor: 2.778

8. Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.

Authors: G L Bakris; L Ruilope; F Locatelli; A Ptaszynska; B Pieske; J de Champlain; M A Weber; I Raz
Journal: Kidney Int Date: 2007-08-01 Impact factor: 10.612

9. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors: Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal: N Engl J Med Date: 2003-11-10 Impact factor: 91.245

Review 10. Effect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis.

Authors: Juan P Casas; Weiliang Chua; Stavros Loukogeorgakis; Patrick Vallance; Liam Smeeth; Aroon D Hingorani; Raymond J MacAllister
Journal: Lancet Date: 2005-12-10 Impact factor: 79.321